FDA's Revised Strategic Plan Emphasizes Countermeasures, Biosimilars
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.
Other aspects of FDA's approach to drugs and biologics remain the same as they were in last September's draft version of the agency's five-year plan.